Yixuan Yu

P.R. China
Beijing, 100029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review.

Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review.

Journal: Oncology letters

Published: November 15, 2024

Machine learning-based screening for biomarkers of psoriasis and immune cell infiltration.

Machine learning-based screening for biomarkers of psoriasis and immune cell infiltration.

Journal: European journal of dermatology : EJD

Published: July 11, 2023

Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.

Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.

Journal: International immunopharmacology

Published: February 20, 2023

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis.

Journal: Journal of oncology

Published: November 30, 2022

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study.

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study.

Journal: Medicine

Published: November 19, 2022

Letter re: Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

Letter re: Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 02, 2022

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.

Journal: Frontiers in immunology

Published: October 01, 2022

Suggestions on "Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer".

Suggestions on "Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer".

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 03, 2022

Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.

Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.

Journal: Frontiers in oncology

Published: May 02, 2022

Radiation induced lung injury (RILI) after postoperative intensity modulated proton therapy (IMPT) in a patient with stage III locally advanced lung adenocarcinoma: a case report.

Radiation induced lung injury (RILI) after postoperative intensity modulated proton therapy (IMPT) in a patient with stage III locally advanced lung adenocarcinoma: a case report.

Journal: Translational cancer research

Published: February 06, 2022

Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma.

Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma.

Journal: Journal of oncology

Published: January 25, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026